Morgensztern, D., Cobo, M., Ponce Aix, S., Postmus, P., Lewanski, C., Bennouna, J., . . . Investigators, O. B. O. T. A. L. (2018). ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC). Wiley.
Chicago Style (17th ed.) CitationMorgensztern, D., et al. ABOUND.2L+: A Randomized Phase 2 Study of Nanoparticle Albumin‐bound Paclitaxel with or Without CC‐486 as Second‐line Treatment for Advanced Nonsquamous Non‐small Cell Lung Cancer (NSCLC). Wiley, 2018.
MLA citiranjeMorgensztern, D., et al. ABOUND.2L+: A Randomized Phase 2 Study of Nanoparticle Albumin‐bound Paclitaxel with or Without CC‐486 as Second‐line Treatment for Advanced Nonsquamous Non‐small Cell Lung Cancer (NSCLC). Wiley, 2018.